Noven Announces Phase III Results for Investigational Non-Hormonal Therapy for Vasomotor Symptoms

Noven Pharmaceuticals announced top-line results from the first of two planned Phase III clinical studies evaluating low-dose mesylate salt of paroxetine for the treatment of vasomotor symptoms associated with menopause.
Yahoo! Finance